dissemination – Page 37 – Communicable Diseases Research

SARS-CoV-2 within-host diversity and transmission

SARS-CoV-2 호스트 내 다양성 및 전송

Research Article

Published on 2021-04-162022-09-10
Journal: Science (New York, N.y.) [Category] MERS, SARS, 변종,

A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial

SARS-CoV-2 백신(비활성화, Vero 세포)의 효능과 안전성을 평가하기 위한 무작위 이중 맹검 위약 대조 임상 3상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-132022-09-10
Journal: Trials [Category] MERS, SARS, 비임상, 임상, 치료기술,

[키워드] 1:1 24 hour 24 hours 95% confidence interval Activation Active surveillance administration Administrative Personnel Adverse adverse event adverse events Adverse reaction Adverse reactions African green monkey age Algorithm Aluminium aluminium hydroxide anaphylaxis Antibody test Antibody titer Antigen Arm asplenia assigned assumed assumption Autoimmune baseline bleeding disorders Blinding blood product blood products blood sample Blood samples breastfeeding women breath carried Cell culture China chloride Clinical efficacy clinical trial code Cohort cohorts comparator consent form cooperation Corticosteroid Corticosteroids COVID-19 COVID-19 cases COVID-19 disease COVID-19 symptoms COVID-19 test criteria Critical CRO Data and Safety Monitoring Board Day development diary dihydrogen DIHYDROGEN PHOSPHATE disease disodium disodium hydrogen phosphate dissemination dose dose of vaccination double blind double-blind double-blind study Efficacy Efficacy and safety element eligible Endpoint enrolled enrolment ethics committee evaluate event excluded exclusion criteria expected Follow-up follow-up period Frequency Gender genders green monkey group groups healthcare Healthcare professional healthcare professionals higher risk HIV infection hospital Hospitalization hydrogen Hydrogen phosphate hydroxide hypersensitivity identity IgG level IgG levels IgG test immunogenicity Immunoglobulin immunoglobulins immunosuppressive immunosuppressive therapy inactivated Inactivated Vaccines incidence incidence rate include Inclusion individual information informed consent form initiated Interactive Web Response System intramuscular dose investigator IWRS IWRS system kidney knowledge Local local reactions management medical doctors medical emergency Ministry of Health mortality rates neutralizing antibody Neutralizing antibody titer Novel coronavirus number Nurses objective Omega Other participant PCR PCR positivity performed Phase III Clinical Trial phosphate Placebo placebo group placebo-controlled positive pregnancy test pregnant preparation primary efficacy endpoint professional proportion protocol randomised randomised controlled trial randomised placebo controlled trial randomization Randomized Randomly Reactions receive recorded regimens Registration reported response risk risk of infection RT-PCR RT-PCR test RT-PCR tests Safety Monitoring Board Sample size SARS-CoV-2 vaccine SARS-CoV-2 virus screened second dose secondary Secondary objectives Serious Adverse Event Serious Adverse Events seroconversion rate Seropositivity severity severity of COVID-19 shown Sinovac sodium Sodium chloride sodium dihydrogen phosphate Sponsor status study group Study protocol subject subject’ supplementary material Symptom symptomatic symptomatic case symptomatic cases System systemic adverse reaction the ethics committee the timing the vaccine therapy Treatment treatment arm Trial Turkey two-sided vaccinated groups vaccination Vaccine Vero Vero Cell Web website width with COVID-19 within 6 months
[DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter

Vaccine development for emerging infectious diseases

Reviews

Published on 2021-04-122022-10-05
Journal: Nature Medicine [Category] SARS, 비임상, 임상, 진단,

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

경증 또는 중등도의 COVID-19 폐렴으로 입원한 환자를 위한 염증 신호 억제제(MATIS)의 다군 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-122022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hours accounted Administered age agreement All participants Allergic reactions approved baseline blind blinded Blinding block Breastfeeding Caregivers cell proliferation childbearing potential clinical clinical outcomes clinically suspected college comparator completion Compliance Concomitant medication Contraception Controlled trial coronavirus COVID-19 COVID-19 disease COVID-19 pneumonia CPAP CRP Data monitoring committee Day death defined Desaturation determine diagnosed disease disease severity dissemination dose drug ECMO effective Efficacy element English enrolment exclusion experimental arm experimental intervention facemask FOS fostamatinib generate GRADE grade 3 Graft graft-versus-host-disease hepatic dysfunction hospital Hospital admission Hospital stay hospitalisation hospitalised patient Hospitalised patients Immune thrombocytopenia Imperial College Healthcare NHS Trust incidence information Informed consent inhibitor Inpatient Inpatients Intervention invasive Invasive mechanical ventilation invasive ventilation investigational agent investigator JAK1 JAK2 janus kinase Kinase inhibitor kinases Laboratory male participants MATIS Mild minimum moderate Moderate COVID-19 moderate to severe Modification multi-arm myelofibrosis nasal oxygen NHS Non-invasive non-invasive ventilation number objective Obstructive obstructive sleep apnoea opinion Ordinal Scale outcome oxygen Pairwise comparison pandemic parallel-group participant Patient Pneumonia polycythaemia vera principal investigator product progression promise proportion protocol random randomisation randomised randomised controlled trial receiving recruit recruited reduce reduce mortality reducing renal impairment renal replacement therapy replacement therapy required Requirement ruxolitinib Sample size sample size calculation Sample size calculations SARS-CoV2 infection scale Secondary objectives selective sequence severe allergic reaction Severe COVID-19 pneumonia severity severity of COVID-19 sexual intercourse signal sleep apnoea Sperm sperm donation spleen Splenomegaly Stage stage 2 Standard Standard of care statistical analysis status Stratification study drug Study protocol supplementary material Symptom systemic inflammation the WHO therapy thrombocytopenia translation Treatment Trial Trial registration Trust tyrosine tyrosine kinase inhibitor Venous Thromboembolism verbal website WHO with COVID-19
[DOI] 10.1186/s13063-021-05190-z PMC 바로가기 [Article Type] Letter

Therapeutic respiratory and functional rehabilitation protocol for intensive care unit patients affected by COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19의 영향을 받는 중환자실 환자를 위한 치료 호흡 및 기능 재활 프로토콜: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-122022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 6-minute walk test activities activity Admission Adult patients affected age Agitation approved assessment balanced randomization blinded Blinding block blocks Borg both groups Care clinical status clinical trial Coma Comorbidities Comorbidity comparator conducted confidentiality cooperation COVID-19 criteria Critical Critical illness daily living Data collection defined discharge dissemination distribution of patient double-blind Douro Dyspnea Effect element eligible Endpoint evaluate evaluated evaluator exertion expected Follow-up for inclusion form functional functional capacity functional rehabilitation Glasgow coma scale group Handgrip strength test Health Health Service Health services Hospital stay Hospitalization Hospitalized hospitalized COVID-19 patients ICU incidence include independent intensive care intensive care unit Intervention intervention group life mechanical ventilation Medical Research Council Medicine Mobility Monday need for oxygen number Nurse nursing care objective occupational therapy occur outcome outcome measure outcomes oxygen Oxygen therapy participant Participants Patient per day Perceived physical Physical assessment physical rehabilitation Physiotherapist Physiotherapy Portugal positioning post-intensive care syndrome Potential Potential participants primary outcome measure progression protocol Quality of life question randomisation randomised randomised controlled trial randomization sequence Randomized Randomized controlled trial readmission reassurance receive recommendation recorded recruited referred to Registered registry rehabilitation rehabilitation exercises rehabilitation medicine respiratory respiratory insufficiency respiratory rehabilitation Respiratory system responsible Sample size Saturday scale Secondary objectives sequence Sex Society stability standard care Standard of care status strength test study group Study protocol subject suctioning supplementary material survey survival Test the patient therapy Tolerance treated Treatment Trial registration two groups verbal website
[DOI] 10.1186/s13063-021-05210-y PMC 바로가기 [Article Type] Letter

The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial

중증 COVID-19 환자에서 N-아세틸시스테인의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-122022-09-10
Journal: Trials [Category] 임상,

[키워드] 1:1 Acetylcysteine Activation Acute respiratory infection addition Admission All participant All participants antioxidant effect antioxidant effects appearance approved Arm assigned Bandar Abba Bandar Abbas baseline Blinding block randomization Care caused cell damage clinical clinical condition clinical trial clinical trials Committee comparator Comparator group composite endpoint control group Controlled clinical trial COVID-19 discharge dissemination dose Effects Efficacy element ethics committee evaluate excluded expected FIVE Health Health care help Hospitalization hypersensitivity Hypoxemia infiltration inflammatory factors injection intensive care intensive care unit Intervention intervention group Intravenous injection investigator Lactate lactate dehydrogenase LDH lead Local lung lung failure lymphopenia mechanical ventilation Medical Science Medical Sciences medication minute N-acetylcysteine number objective outcome oxygen oxygen partial pressure parallel-group partial pressure participant Patient patients Pharmaceutical Company Phase 3 Placebo positive PCR test Pregnancy primary endpoint principal investigator Progressive protocol random randomised randomised controlled trial randomization Randomized Randomly reactive oxygen species receive recruitment Registered registry reported respiration rate respiratory infection Saline Sample size SARI SARS-CoV-2 virus sequence severe COVID-19 severe COVID-19 patient severe COVID-19 patients Side effect Standard Standard of care Sterile sterile water Study protocol supplementary material technology test results the ethics committee the patient the SARS-CoV-2 virus Treatment Trial registration university water water for injection website were measured written consent
[DOI] 10.1186/s13063-021-05242-4 PMC 바로가기 [Article Type] Letter

COVID-19 Research: Challenges to Interpret Numbers and Propose Solutions

Public Health

Published on 2021-04-122022-10-31
Journal: Frontiers in Public Health [Category] COVID-19, MERS, SARS,

Supporting Parents & Kids Through Lockdown Experiences (SPARKLE) : A digital parenting support app implemented in an ongoing general population cohort study during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial

Lockdown Experiences(SPARKLE)를 통해 부모와 자녀 지원 : COVID-19 전염병 동안 진행 중인 일반 인구 집단 연구에서 구현된 디지털 육아 지원 앱: 무작위 통제 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-102022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 adverse events Analysis automatically baseline baseline characteristics blind blinded Blinding changes in Child behaviour problems children clinical Cohort cohort study collected Community comparator Complete Controlled trial COVID-19 difficulty Digital health dissemination Effect Efficacy eight element eligible enrolled exacerbated examined experience Exploratory analyses facilitated Families FAU General population Graphics help implementation individual information Intervention lockdown longitudinal cohort study measure mental health moderate number objective on children outcome outcomes pandemic parallel group parent Parenting parents participant platform Pragmatic Primary outcome problem protocol provided public health Public health intervention Qualtrics randomisation randomised randomised controlled trial receive recruited reduce Registered reported Research resources Sample size selected senior statistician Space Standard Stratification strength Stress Study protocol supplementary material Support Supporting text treatment arm Trial Two-arm Usage was selected website
[DOI] 10.1186/s13063-021-05226-4 PMC 바로가기 [Article Type] Letter

SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs

Review

Published on 2021-04-102022-10-29
Journal: Microorganisms [Category] COVID-19,

[키워드] ACE2 ACE2 receptor acute respiratory syndrome affected antigenic China coronavirus Cytokine Storm Syndrome (CSS) diagnostic test diagnostics diffusion dissemination droplets effective Efficacy furin globe host cell identify IMPROVE Infection infective agent manifestation mechanism Microbiome molecular test nasal novel occur oral mucosa oral mucosa (salivary glands) pandemic passages persistence Prevent Rapid reduction RT-PCR Saliva SARS-CoV-2 SARS-CoV-2 (COVID-19 pandemic) SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2 variant Spread subject the SARS-CoV-2 TMPRSS2 vaccination Vaccine Vaccines virulence virus World Health Organization
[DOI] 10.3390/microorganisms9040793 PMC 바로가기 [Article Type] Review

Primary Care implementation of Germ Defence, a digital behaviour change intervention to improve household infection control during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial

COVID-19 전염병 동안 가정 감염 통제를 개선하기 위한 디지털 행동 변화 개입인 Germ Defence의 1차 진료 구현: 무작위 통제 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-092022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 antibiotic Behaviour change blinded Blinding block blocks Bristol Care clinical Cluster collaboration Commission comparator Contact Controlled trial coronavirus COVID-19 COVID-19 symptom detect diagnose Digital health Digital medicine dissemination Effect effect size Effectiveness element engage England enrolment Gastrointestinal infection gastrointestinal infections general practices Germ group hand washing help Hospital admission hygiene identity implementation IMPROVE incidence incidence of COVID-19 include independent individual Infection infection control Infectious disease Intervention intervention arm involved ISRCTN ISRCTN registry management measure number objective outcome overcome participant Patient personalised Prevalence primary care Primary outcome Principal Investigators problem problem solving protection protocol randomisation randomised randomised controlled trial Randomly receive reduce Registered respiratory respiratory tract infection Sample size secondary outcome Secondary outcomes Spread Stata Statistical Software statistical statistician Study protocol supplementary material Symptom Trial Trial registration Two-arm usual care website
[DOI] 10.1186/s13063-021-05188-7 PMC 바로가기 [Article Type] Letter